)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Zydus Lifesciences (ZYDUSLIFE) investor relations material
Zydus Lifesciences Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 25/26 earnings summary6 Nov, 2025
Executive summary
Achieved robust financial performance in Q2 FY26, with consolidated revenues from operations reaching INR 61.2 billion, up 17% year-on-year, and net profit at INR 12.6 billion, a 38% YoY increase, driven by strong growth across India, US, and international markets.
Completed strategic acquisitions of ComfortClick (UK-based VMS platform) and full ownership of Amplitude Surgical, enhancing international and medtech presence.
Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, following Audit Committee recommendations.
Continued focus on innovation, specialty portfolio expansion, and global market reach, especially in the US, Europe, and emerging markets.
Consumer Wellness made its first international acquisition, expanding presence in UK, EU, and US.
Financial highlights
Consolidated revenues reached INR 61.2 billion, up 17% year-on-year; EBITDA margin improved to 32.9% (up 500 bps YoY); EBITDA at INR 20.2 billion, up 38% YoY; net profit for the quarter was INR 12.6 billion, up 38% YoY.
Consumer wellness revenues grew 31% YoY to INR 6.4 billion; international formulations up 39% YoY to INR 7.5 billion.
R&D expenses were INR 4.82 billion, 7.9% of revenues; net gain on foreign currency transactions was INR 4.14 billion.
Standalone revenue from operations for Q2 FY26: INR 28.7 billion, down from INR 29.5 billion in Q2 FY25; standalone net profit for Q2 FY26: INR 11.6 billion, up from INR 7.9 billion in Q2 FY25.
Consolidated revenue from operations for Q2 FY26: INR 61.2 billion, up from INR 52.4 billion in Q2 FY25; consolidated net profit for Q2 FY26: INR 12.6 billion, up from INR 9.1 billion in Q2 FY25.
Outlook and guidance
On track to achieve targeted top-line growth and profitability for FY26, with guidance for 25+ product launches in the US and operating margin guidance of 26%+ for the year.
Preparing to file NDA for Saroglitazar Magnesium with USFDA in Q4 FY26 after positive Phase 2/3 results; regulatory approval received to initiate Phase II clinical trials of Bivalent Typhoid Conjugate Vaccine in India.
Board and management did not provide explicit forward-looking guidance in the disclosed materials.
Targeted therapeutic areas for US specialty M&A
US revenue drivers post-REVLIMID in FY'27
Dialyzer membrane global market and strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Zydus Lifesciences earnings date
Q3 202614 Feb, 2026
Next Zydus Lifesciences earnings date
Q3 202614 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Zydus Lifesciences Limited is an India-based pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company operates across multiple therapeutic areas, including cardiology, dermatology, gastroenterology, oncology, and diabetes care. It provides a range of pharmaceutical products, biologics, vaccines, and active pharmaceutical ingredients (APIs) to domestic and international markets. The company is headquartered in Ahmedabad, India, and its shares are listed on the NSE and BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage